尚庆森 | 博士 | 副教授 | 硕士生导师 | ||
科 室: | 糖化学与海洋糖药物研究室 | ||||
办公电话: | 19157371307 | 电子邮箱: | shangqingsen@ouc.edu.cn | ||
联系地址: | 山东省青岛市香港东路23号青岛海洋生物医药研究院A201 | ||||
研究方向: | 1. 海洋来源功能糖与肠道菌群的互作关系研究; 2. 基于肠道菌群的海洋糖药物的代谢与药理学机制研究; 3.新型益生元与益生菌的分离筛选与产业化开发; | ||||
个人简介 |
|
|
|
| |
主要从事海洋功能性多糖、寡糖与肠道菌群的互作关系研究,包括肠道菌群对海洋功能糖的降解、代谢和海洋功能糖对肠道菌群的调节作用研究。近年来,围绕海洋功能糖与肠道菌群的互作关系,结合厌氧微生物体外模拟发酵、疾病模型体内动物实验及16S rRNA高通量测序技术,对系列海洋多糖的肠道菌群代谢过程及其菌群调节作用进行了系统深入的研究。在J. Clin. Investig.、Carbohydr. Polym.、Int. J. Biol. Macromol.、Toxicol. Lett.、Mar. Drugs、Food Funct.、J. Funct. Foods、Polymers、Anaerobe、Bioact. Carbohydr. Diet. Fibre等国际知名期刊上发表19篇研究论文,授权国家发明专利2项。 | |||||
教育背景 |
|
|
|
| |
2013年8月至2018年6月 | 中国海洋大学医药学院 | 药物化学 | 博士 | ||
2009年9月至2013年6月 | 青岛科技大学化工学院 | 制药工程 | 学士 | ||
工作经历 |
|
|
|
| |
2020年9月至今 | 中国海洋大学医药学院 | 副教授 |
| ||
2018年9月至2020年6月 | 密西根大学-安娜堡分校医学院 | 博士后 |
| ||
学术兼职 |
|
|
|
| |
担任美国化学学会会员,国际学术期刊Journal of Visualized Experiments和Frontiers in Nutrition客座编辑与Food Hydrocolloids for Health编委。担任化学、药学、微生物学、营养学、食品科学和生物医药领域20余个SCI杂志审稿人。累计为Trends Food Sci. Technol.、Green Chem.、Crit. Rev. Food Sci. Nutr.、Carbohydr. Polym.、Cancers、Microorganisms、Sci. Rep.、J. Funct. Foods、Food Funct.、Nutrients、Mar. Drugs等系列期刊审稿文章100余篇。 | |||||
荣誉奖励 |
|
|
|
| |
1. 2016年10月 博士研究生国家奖学金 2. 2016年10月 8th ACGG Best Poster Award 3. 2017年10月 山东省研究生优秀科技创新成果奖二等奖 4. 2017年10月 博士研究生国家奖学金 5. 2017年11月第十三届海洋药物学术年会优秀论文奖 6. 2020年1月 2019年度山东省优秀博士学位论文 7. 2020年3月 Outstanding Reviewer for Food & Function in 2019 8. 2020年5月Outstanding Reviewer for RSC Advancesin 2019 | |||||
研究进展 |
|
|
|
| |
肠道菌群是寄居在宿主肠道中细菌、真菌和古生菌的总称。作为机体的一个重要组成部分,肠道菌群对宿主的发育、免疫和代谢等生理生化过程具有重要的调控作用。研究表明,肠道菌群紊乱可以引起宿主产生疾病。因此,药物可以通过靶向肠道菌群,改变菌群结构,发挥治疗作用或者诱发毒副反应。海洋多糖是一类海洋动植物来源的、化学结构复杂多变且具有多种生物学作用的水溶性大分子。作为海洋天然产物的重要组成部分,海洋多糖在食品和医药工业中具有广泛的应用。由于该类多糖具有分子量大、耐消化酶水解和口服生物利用度低等特点,其进入消化道后,会与肠道菌群发生互作。因此,研究海洋多糖对肠道菌群结构的影响对阐明其药理学和毒理学作用具有重要意义。近年来,围绕海洋多糖与肠道菌群的互作关系主要取得以下研究成果:1,首次从肠道菌群角度阐明了岩藻聚糖硫酸酯的抗代谢综合征作用和卡拉胶的致肠炎机制,为海洋硫酸多糖的药效学和毒理学研究提供了新视角;2,基于16S rRNA高通量测序技术,首次系统阐明了岩藻聚糖硫酸酯、浒苔多糖、硫酸角质素和硫酸软骨素的肠道菌群调节作用及益生元活性,为海洋来源“新一代”益生元的开发利用提供了理论依据;3,基于厌氧微生物体外模拟发酵技术,首次系统阐明了硫酸软骨素、透明质酸、褐藻胶及琼胶等多糖的肠道菌群代谢过程,为进一步研究口服糖药物的代谢机制提供了理论依据。
| |||||
代表性成果 | |||||
代表性论文(*corresponding author): | |||||
1. Fu, T., Zhou, L., Fu, Z., Zhang, B., Li, Q., Pan, L., Zhou, C., Zhao, Q., Shang, Q. *, & Yu, G. *Enterotype-specific effect of human gut microbiota on the fermentation of marine algae oligosaccharides: A preliminary proof-of-concept in vitro study. Polymers, 2022, 14(4): 770. 2. Pan, L., Fu, T.,Cheng H., Mi J.,Shang, Q. *, & Yu, G. *Polysaccharide from edible alga Gloiopeltisfurcata attenuates intestinal mucosal damage by therapeutically remodeling the interactions between gut microbiota and mucin O-glycans. Carbohydrate Polymers, 2022, 278: 118921. 3. Pan, L., Ai, X., Fu, T., Ren, L., Shang, Q. *, Li, G.*, & Yu, G.* In vitro fermentation of hyaluronan by human gut microbiota: Changes in microbiota community and potential degradation mechanism. Carbohydrate Polymers, 2021,269: 118313. 4. Fu, T., Pan, L., Shang, Q. *, & Yu, G.* Fermentation of alginate and its derivatives by different enterotypes of human gut microbiota: Towards personalized nutrition using enterotype-specific dietary fibers. International Journal of Biological Macromolecules, 2021, 183, 1649-1659. 5. Wei, J., Zhao, Y., Zhou, C., Zhao, Q., Zhong, H., Zhu, X., Fu, T., Pan, L., Shang, Q. *, & Yu, G. * Dietary Polysaccharide from Enteromorpha clathrataattenuates obesity and increases the intestinal abundance of butyrate-producing bacterium, Eubacterium xylanophilum, in mice fed a high-fat diet.Polymers, 2021, 13, 3286. 6. Shang, Q., Jiang, H., Cai, C., Hao, J., Li, G. and Yu, G.*, Gut microbiota fermentation of marine polysaccharides and its effects on intestinal ecology: An overview. Carbohydrate Polymers, 2018, 179, pp.173-185. 7. Shang, Q., Shi, J., Song, G., Zhang, M., Cai, C., Hao, J., Li, G. and Yu, G.*, Structural modulation of gut microbiota by chondroitin sulfate and its oligosaccharide. International Journal of Biological Macromolecules, 2016, 89, pp.489-498. 8. Shang, Q., Yin, Y., Zhu, L., Li, G., Yu, G.* and Wang, X.*, Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals. International Journal of Biological Macromolecules, 2016, 86, pp.112-118. 9. Shang, Q., Shan, X., Cai, C., Hao, J., Li, G. and Yu, G.*, Dietary fucoidan modulates the gut microbiota in mice by increasing the abundance of Lactobacillus and Ruminococcaceae. Food & Function, 2016, 7(7), pp.3224-3232. 10. Shang, Q., Song, G., Zhang, M., Shi, J., Xu, C., Hao, J., Li, G. and Yu, G.*, Dietary fucoidan improves metabolic syndrome in association with increased Akkermansia population in the gut microbiota of high-fat diet-fed mice. Journal of Functional Foods, 2017, 28, pp.138-146. 11. Shang, Q., Sun, W., Shan, X., Jiang, H., Cai, C., Hao, J., Li, G. and Yu, G.*, Carrageenan-induced colitis is associated with decreased population of anti-inflammatory bacterium, Akkermansiamuciniphila, in the gut microbiota of C57BL/6J mice. Toxicology Letters, 2017, 279, pp.87-95. 12. Shang, Q., Li, Q., Zhang, M., Song, G., Shi, J., Jiang, H., Cai, C., Hao, J., Li, G. and Yu, G.*, Dietary keratan sulfate from shark cartilage modulates gut microbiota and increases the abundance of Lactobacillus spp. Marine Drugs, 2016, 14(12), p.224. 13. Shang, Q., Wang, Y., Pan, L., Niu, Q., Li, C., Jiang, H., Cai, C., Hao, J., Li, G. and Yu, G.*, Dietary polysaccharide from Enteromorpha Clathratamodulates gut microbiota and promotes the growth of Akkermansiamuciniphila, Bifidobacterium spp. and Lactobacillus spp. 2018, Marine Drugs, 16(5), p.167. 14. Shang, Q.*,From correlation to causation: The missing point in the study of functional foods and gut microbiota. Journal of Functional Foods, 2019, 61, 103466. 15. Shang, Q.*, Revisit the effects of fucoidan on gut microbiota in health and disease: What do we know and what do we need to know? Bioactive Carbohydrates and Dietary Fibre, 2020, 23, 100221. 16. Li, M., Shang, Q., Li, G., Wang, X.* and Yu, G.*, Degradation of marine algae-derived carbohydrates by Bacteroidetes isolated from human gut microbiota. Marine Drugs, 2017, 15(4), p.92. 17. Li, M., Li, G., Shang, Q., Chen, X., Liu, W., Zhu, L., Yin, Y., Yu, G.* and Wang, X.*, In vitro fermentation of alginate and its derivatives by human gut microbiota. Anaerobe, 2016, 39, pp.19-25. 18. Liu, Y., Lin, H., Jiang, L., Shang, Q., Yin, L., Lin, J.D., Wu, W.S. and Rui, L.*, Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes. Journal of Clinical Investigation. 2020, 130(6), 2992-3004. 19. Pan, L., Sun, W., Shang, Q., Niu, Q., Liu, C., Li, G.*, & Yu, G.*In Vitro Fermentation and Isolation of Heparin-degrading Bacteria from Human Gut Microbiota. Anaerobe, 2020, 102289. | |||||
专利 |
|
|
|
| |
| |||||
项目课题 | |||||
| |||||